Abstract: A method of detecting cancer in mammals which comprises admixing with a serum sample from said mammal detectably labelled acyl carrier protein and subsequently determining the amount of B-protein-acyl carrier protein complex which is formed.

Abstract: A method of detecting cancer in mammals which comprises precipitating at least a portion of the proteins in a serum sample from a mammal and then measuring the rate at which said precipitated proteins are re-solubilized.

Abstract: A process for preparing CoA-SPC Bakers' yeast extract which comprises:lysing Bakers' yeast cells;separating the Bakers' yeast cell lysate into solid and supernatant fractions wherein said solid fraction is substantially free of t-factor;treating said solid fraction to solubilize insoluble proteinaceous material other than the insoluble CoA-SPC;separating said solubilized proteinaceous materials from the fraction containing said insoluble CoA-SPC; andcontacting said fraction containing said insoluble CoA-SPC with said supernatant fraction containing t-factor to produce soluble CoA-SPC.

Abstract: CoA-SPC Bakers' yeast extract which is substantially free of proteolytic enzymes.

Abstract: A specific type of protein, which has been designated B-protein (Bucovaz-protein), is present in most serum of individuals with cancer. The B-protein interacts with a low molecular weight protein component, which is released by the coenzyme A-synthesizing protein complex (CoA-SPC) of Bakers' yeast during the course of CoA synthesis. This low molecular weight protein, for purposes of identification, is referred to as binding protein. The binding protein has a molecular weight of 10,000 to 15,000. Interaction of radioactively labeled binding protein of CoA-SPC with the B-protein of serum provides a marker for the detection of cancer. Of 3005 serums assayed, which included 908 patients diagnosed as having cancer, the B-protein assay agreed with the clinical diagnosis in more than 89% of the cases.

Abstract: A specific type of protein, which has been designated B-protein (Bucovaz-protein), is present in most serum of individuals with cancer. The B-protein interacts with a low molecular weight protein component, which is released by the coenzyme A-synthesizing protein complex (CoA-SPC) of Bakers' yeast during the course of CoA synthesis. This low molecular weight protein, for purposes of identification, is referred to as binding protein. The binding protein has a molecular weight of 10,000 to 15,000. Interaction of radioactively labeled binding protein of CoA-SPC with the B-protein of serum provides a marker for the detection of cancer. Of 3005 serums assayed, which included 908 patients diagnosed as having cancer, the B-protein assay agreed with the clinical diagnosis in more than 89% of the cases.